KAPA

Kairos Pharma Ltd

0.5585

Oct 23 • 3:59 PM ET +0.0145 (2.67%)

0.5430

Aftermarket • 7:30 PM ET -0.0155 (-2.78%)

Healthcare Biotechnology USA Nano AMEX

Peers: LIMN KYNB APVO HCWB MBRX VERU ONCO ATNM ELTX XBIT

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	1.89M
Enterprise Value	-0.74M
Income	-5.80M
Sales	0.00M
Book/sh	1.37
Cash/sh	0.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Sep 16, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.41
P/C	0.72
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.98
Current Ratio	11.98
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.95
EPS next Y	-3.54
EPS next Q	-0.56
EPS this Y	-10.00%
EPS next Y	-53.03%
EPS next 5Y	-22.76%
EPS past 3/5Y	-53.50% -29.28%
Sales past 3/5Y	- -
EPS Y/Y TTM	11.64%
Sales Y/Y TTM	-
EPS Q/Q	21.56%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	33.61%
Insider Trans	0.00%
Inst Own	4.08%
Inst Trans	7.84%
ROA	-104.32%
ROE	-113.96%
ROIC	-138.51%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-44.01%
SMA50	-62.61%
SMA200	-82.48%
Trades

Shs Outstand	3.06M
Shs Float	2.25M
Short Float	5.03%
Short Ratio	0.30
Short Interest	0.11M
52W High	8.12 -93.12%
52W Low	0.52 7.09%
Volatility	13.02% 18.16%
ATR (14)	0.15
RSI (14)	18.87
Beta	1.65
Rel Volume	0.30
Avg Volume	375.03K
Volume	112,904

Perf Week	-7.12%
Perf Month	-68.45%
Perf Quarter	-74.25%
Perf Half Y	-86.86%
Perf YTD	-88.76%
Perf Year	-92.68%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	49.00
Prev Close	0.54
Price	0.56
Change %	2.67%

Oct-06-26 07:30AM	Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer (Business Wire) -25.81%
Sep-23-26 08:00AM	Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA (Business Wire)
Sep-09-26 08:00AM	Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire) -6.21%
Aug-21-26 04:30PM	Kairos Pharma Announces 1-for-7 Reverse Stock Split (Business Wire) -20.00%
Jul-22-26 08:35AM	Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer (Business Wire) -12.65%
08:39AM	Loading…
Jul-15-26 08:39AM	CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever (TMX Newsfile) -6.47%
08:30AM	Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients - Targeting a $10 Billion Drug Resistance Market (Business Wire)
Jun-04-26 08:00AM	Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders (Business Wire)
May-14-26 08:00AM	Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award (Business Wire) +6.10%
May-13-26 05:30AM	Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI (Newsfile)
May-08-26 04:30PM	Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings (Business Wire) -5.36%
Apr-15-26 09:00AM	Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation (Business Wire)
Mar-03-26 05:54AM	Kairos Pharma signs deal for Celyn Therapeutics CL-273 (Pharmaceutical Technology)
Mar-02-26 06:30AM	Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics (Business Wire)
Feb-26-26 07:00AM	Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics (Business Wire) -12.15%
07:25AM	Loading…
Sep-19-25 07:25AM	Kairos Pharma reports positive data from Phase II prostate cancer treatment trial (Clinical Trials Arena) -8.96%
Jul-28-25 12:28PM	CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline (Newsfile) -6.09%
Jul-16-25 08:30AM	Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 (Business Wire) -6.84%
Jul-15-25 08:00AM	Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer (Business Wire) +70.78%
Jun-03-25 08:15AM	Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Business Wire) -23.51%
May-06-25 08:00AM	Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-28-25 08:00AM	Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Business Wire)
Apr-24-25 08:00AM	Kairos Pharma Ltd. Provides Letter to Stockholders (Business Wire)
Apr-17-25 08:00AM	Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer (Business Wire) +5.80%
Apr-04-25 09:40AM	Block upgraded, Nvidia downgraded: Wall Streets top analyst calls (TipRanks) +12.77%
Mar-31-25 07:00AM	Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer (Business Wire)
Mar-28-25 09:03AM	CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105 (Newsfile) -5.01%
Mar-27-25 04:05PM	Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events (Business Wire)
Mar-20-25 07:30AM	Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer (Business Wire)
Feb-26-25 07:00AM	Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds Potential as Therapeutics for Melanoma and Glioblastoma (Business Wire) +8.77%
08:30AM	Loading…
Feb-18-25 08:30AM	Kairos Pharma Announces New Department of Defense Funding for Research of ENV205 (Business Wire)
Feb-11-25 08:30AM	Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial (Business Wire)
Feb-06-25 08:30AM	Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compounds Potential as a Therapeutic for Melanoma and Glioblastoma (Business Wire) -8.86%
Jan-28-25 08:15AM	Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 (Business Wire)
Jan-21-25 08:30AM	Kairos Pharma Provides Business Update and Outlook into 2025 (Business Wire) -8.09%
Jan-07-25 08:15AM	Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit (Business Wire)
Dec-16-24 12:15PM	Kairos Pharma to Participate in The Microcap Conference in January 2025 (ACCESSWIRE)
Dec-03-24 08:30AM	Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial (Business Wire)
Nov-19-24 08:30AM	Kairos Pharma Approved to Dual List on Upstream (GlobeNewswire) -14.04%
Oct-22-24 09:00AM	Kairos Pharma to Present at the LD Micro Main Event XVII (GlobeNewswire)
Oct-14-24 06:00AM	Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges (News Direct) +7.80%
Oct-09-24 04:30PM	Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-24-24 04:20PM	Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients (GlobeNewswire) -7.46%
Sep-17-24 04:29PM	Kairos Pharma Closing of $6.2 Million Initial Public Offering (GlobeNewswire) -5.38% -6.50%
Sep-16-24 10:49AM	Kairos Pharma Prices $6.2 Million Initial Public Offering (GlobeNewswire)

Show Previous News

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

Ph.D.Dr. John S. Yu M.D.

Chief Financial OfficerMr. Douglas W. Samuelson CPA

Chief Scientific OfficerDr. Neil A. Bhowmick Ph.D.

Vice President of Research & DevelopmentDr. Ramachandran Murali Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KAPA

Kairos Pharma Ltd

Upgrade your Finviz experience